Chipping away at breast cancer: Insights from microarray studies of human and mouse mammary cancer

Endocrine-Related Cancer

Volumn 9, Issue 4, 2002, Pages 207-220

  Desai, K V ^a   Kavanaugh, C J ^a   Calvo, A ^a   Green, J E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL X; PROTEIN MDM2; PROTEIN P53; RAD51 PROTEIN;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CELL CYCLE; CELL GROWTH; CELL SURVIVAL; DNA MICROARRAY; GENE EXPRESSION; GENE MUTATION; HUMAN; NONHUMAN; REVIEW; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 0037001152     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0090207     Document Type: Review

References (107)

1. Allred DC, Mohsin SK & Fuqua SA 2001 Histological and biological evolution of human premalignant breast disease. Endocrine-Related Cancer 8 47-61.
2. Alter O, Brown PO & Botstein D 2000 Singular value decomposition for genome-wide expression data processing and modeling. PNAS 97 10101-10106.
3. Bange J, Zwick E & Ullrich A 2001 Molecular targets for breast cancer therapy and prevention. Nature Medicine 7 548-552.
4. Barrett-Connor E 2001 Raloxifene: risks and benefits. Annals of the New York Academy of Sciences 949 295-303.
5. Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE, Koester SK, Troyer DA, Bearss DJ, Conner MW, Gibbs JB, Hamilton K, Koblan KS, Mosser SD, O'Neill TJ, Schaber MD, Senderak ET, Windle JJ, Oliff A & Kohl NE 1998 A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Molecular and Cellular Biology 18 85-92.
6. Berns EM, de Klein A, van Putten WL, van Staveren IL, Bootsma A, Klijn JG & Foekens JA 1995 Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival. International Journal of Cancer 64 140-145.
7. Bieche I & Lidereau R 1995 Genetic alterations in breast cancer. Genes, Chromosomes and Cancer 14 227-251.
8. Bier FF & Kleinjung F 2001 Feature-size limitations of microarray technology - a critical review. Fresenius Journal of Analytical Chemistry 371 151-156.
9. Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S & Liotta LA 1997 Laser capture microdissection: molecular analysis of tissue. Science 278 1481-1483.
10. Bouchard L, Lamarre L, Tremblay PJ & Jolicoeur P 1989 Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57 931-936.
11. Brodie SG, Xu X, Li C, Kuo A, Leder P & Deng CX 2001 Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis. Oncogene 20 1445-1454.
12. Burke HB 2000 Discovering patterns in microarray data. Molecular Diagnostics 5 349-357.
13. Bustin SA 2000 Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. Journal of Molecular Endocrinology 25 169-193.
14. Cardiff RD 2001 Validity of mouse mammary tumour models for human breast cancer: comparative pathology. Microscopy Research and Techniques 52 224-230.
15. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM & Green JE 2000 The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19 968-988.
16. Clavel M & Catimel G 1993 Breast cancer: chemotherapy in the treatment of advanced disease. European Journal of Cancer 29A 598-604.
17. Cook-Bruns N 2001 Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61 (Suppl 2) 58-66.
18. Craven RA, Totty N, Harnden P, Selby PJ & Banks RE 2002 Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. American Journal of Pathology 160 815-822.
19. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjamason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A & Jordan VC 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Journal of the American Medical Association 281 2189-2197.
20. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S & Theillet C 2000 Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Research 60 1077-1083.
21. Dankort DL & Muller WJ 2000 Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene 19 1038-1044.
22. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL & Fisher B 1999 Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of Clinical Oncology 17 2659-2669.
23. Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, Simon R, Liu ET & Green JE 2002 Initiating oncogenic event determines gene-expression patterns of human breast cancer models. PNAS 99 6967-6972.
24. Dexter DL, Diamond M, Creveling J & Chen SF 1993 Chemotherapy of mammary carcinomas arising in ras transgenic mice. Investigational New Drugs 11 161-168.
25. Dorr A 1990 Adjuvant therapy in breast cancer. Current Opinion in Oncology 2 1049-1052.
26. Dorssers LC, Van der FS, Brinkman A, van Agthoven T, Veldscholte J, Bems EM, Klijn JG, Beex LV & Foekens JA 2001 Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61 1721-1733.
27. Draghici S, Kuklin A, Hoff B & Shams S 2001 Experimental design, analysis of variance and slide quality assessment in gene expression arrays. Current Opinion in Drug Discovery and Development 4 332-337.
28. Drmanac S & Drmanac R 1994 Processing of cDNA and genomic kilobase-size clones for massive screening, mapping and sequencing by hybridization. Biotechniques 9 332-336.
29. Eisen MB & Brown PO 1999 DNA arrays for analysis of gene expression. Methods in Enzymology 303 179-205.
30. Ellis M, Davis N, Coop A, Liu M, Schumaker L, Lee RY, Srikanchana R, Russell CG, Singh B, Miller WR, Steams V, Pennanen M, Tsangaris T, Gallagher A, Liu A, Zwart A, Hayes DF, Lippman ME, Wang Y & Clarke R 2002 Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clinical Cancer Research 8 1155-1166.
31. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA & Liotta LA 1996 Laser capture microdissection. Science 274 998-1001.
32. Ermolaeva O, Rastogi M, Pruitt KD, Schuler GD, Bittner ML, Chen Y, Simon R, Meltzer P, Trent JM & Boguski MS 1998 Data management and analysis for gene expression arrays. Nature Genetics 20 19-23.
33. Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT & Davidson NE 1997 Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells. Journal of Biological Chemistry 272 32260-32266.
34. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L & Wolmark N 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 90 1371-1388.
35. Fodor SP, Rava RP, Huang XC, Pease AC, Holmes CP & Adams CL 1993 Multiplexed biochemical assays with biological chips. Nature 364 555-556.
36. Ford D, Easton DF, Bishop DT, Narod SA & Goldgar DE 1994 Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343 692-695.
37. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M et al. 1998 Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. American Journal of Human Genetics 62 676-689.
38. Frame S & Balmain A 2000 Integration of positive and negative growth signals during ras pathway activation in vivo. Current Opinion in Genetic Development 10 106-113.
39. Greenlee RT, Murray T, Bolden S & Wingo PA 2000 Cancer statistics, 2000. A Cancer Journal for Clinicians 50 7-33.
40. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C & Meltzer PS 2001 Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Research 61 5979-5984.
41. Guy CT, Cardiff RD & Muller WJ 1992 Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Molecular and Cellular Biology 12 954-961.
42. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P & Muller WJ 1994 Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes and Development 8 23-32.
43. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A & Trent J 2001 Gene-expression profiles in hereditary breast cancer. New England Journal of Medicine 344 539-548.
44. Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, Lefkowitz SM, Ziman M, Schelter JM, Meyer MR, Kobayashi S, Davis C, Dai H, He YD, Stephaniants SB, Cavet G, Walker WL, West A, Coffey E, Shoemaker DD, Stoughton R, Blanchard AP, Friend SH & Linsley PS 2001 Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nature Biotechnology 19 342-347.
45. Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Barrington RE & Windle JJ 1997 Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. Cancer Research 57 600-603.
46. Janocko LE, Brown KA, Smith CA, Gu LP, Pollice AA, Singh SG, Julian T, Wolmark N, Sweeney L, Silverman JF & Shackney SE 2001 Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. Cytometry 46 136-149.
47. Kavanaugh CJ, Desai KV, Calvo A, Brown PH, Couldrey C, Lubert R & Green JE 2002 Pre-clinical applications of transgenic mouse mammary cancer models. Transgenic Research (In Press).
48. Kerr MK & Churchill GA 2001 Statistical design and the analysis of gene expression microarray data. Genetical Research 77 123-128.
49. Ketcham AS & Sindelar WF 1975 Risk factors in breast cancer. Progress in Clinical Cancer 6 99-114.
50. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C & Meltzer PS 2001 Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Medicine 7 673-679.
51. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K et al. 1995 Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Medicine 1 792-797.
52. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Easton DF et al. 1998 Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. Journal of the National Cancer Institute 90 1138-1145.
53. Leder A, Pattengale PK, Kuo A, Stewart TA & Leder P 1986 Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 45 485-495.
54. Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, Shields PG, Modali R & Turner BC 2000 Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Research 60 1062-1069.
55. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J & Anderson RL 1999 A novel orthotopic model of breast cancer metastasis to bone. Clinical and Experimental Metastasis 17 163-170.
56. Levi MS, Borne RF & Williamson JS 2001 A review of cancer chemopreventive agents. Current Medical Chemistry 8 1349-1362.
57. Li H & Hong F 2001 Cluster-Rasch models for microarray gene expression data. Genome Biology 2 RESEARCH0031.
58. Lidereau R, Mathieu-Mahul D, Escot C, Theillet C, Champeme MH, Cole S, Mauchauffe M, Ali I, Amione J, Callahan R et al. 1988 Genetic variability of proto-oncogenes for breast cancer risk and prognosis. Biochimie 70 951-959.
59. Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH & Hunter KW 1998 Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. International Journal of Cancer 77 640-644.
60. Lockhart DJ & Winzeler EA 2000 Genomics, gene expression and DNA arrays. Nature 405 827-836.
61. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M & Olsson H 1998 Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83 310-319.
62. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD & MacLeod CL 2001 Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Research 61 8298-8305.
63. Maroulakou IG, Anver M, Garrett L & Green JE 1994 Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. PNAS 91 11236-11240.
64. Maroulakou IG, Shibata MA, Anver M, Jorcyk CL, Liu M, Roche N, Roberts AB, Tsarfaty I, Reseau J, Ward J & Green JE 1999 Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-betal and BMP-2 expression. Oncogene 18 5435-5447.
65. Menard S, Aiello P, Tagliabue E, Rumio C, Lollini PL, Colnaghi MI & Balsari A 2000 Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Research 60 273-275.
66. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al. 1994 A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 66-71.
67. Miles MF 2001 Microarrays: lost in a storm of data? Nature Review Neuroscience 2 441-443.
68. Miller KD & Sledge GW Jr 1999 Taxanes in the treatment of breast cancer: a prodigy comes of age. Cancer Investigation 17 121-136.
69. Nandi S, Guzman RC & Yang J 1995 Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. PNAS 92 3650-3657.
70. Nathanson KL, Wooster R, Weber BL & Nathanson KN 2001 Breast cancer genetics: what we know and what we need. Nature Medicine 7 552-556.
71. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB & Davidson NE 1994 Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Research 54 2552-2555.
72. Pattengale PK, Stewart TA, Leder A, Sinn E, Muller W, Tepler I, Schmidt E & Leder P 1989 Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes. American Journal of Pathology 135 39-61.
73. Perou CM, Jeffrey SS, van de RM, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO & Botstein D 1999 Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. PNAS 96 9212-9217.
74. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO & Botstein D 2000 Molecular portraits of human breast tumours. Nature 406 747-752.
75. Peto J & Mack TM 2000 High constant incidence in twins and other relatives of women with breast cancer. Nature Genetics 26 411-414.
76. Quackenbush J 2001 Computational analysis of microarray data. Nature Review. Genetics 2 418-427.
77. Ramakrishnan R, Dorris D, Lublinsky A, Nguyen A, Domanus M, Prokhorova A, Gieser L, Touma E, Lockner R, Tata M, Zhu X, Patterson M, Shippy R, Sendera TJ & Mazumder A 2002 An assessment of Motorola CodeLink(TM) microarray performance for gene expression profiling applications. Nucleic Acids Research 30 1-12.
78. Raychaudhuri S, Sutphin PD, Chang JT & Altman RB 2001 Basic microarray analysis: grouping and feature reduction. Trends in Biotechnology 19 189-193.
79. Runnebaum IB, Nagarajan M, Bowman M, Soto D & Sukumar S 1991 Mutations in p53 as potential molecular markers for human breast cancer. PNAS 88 10657-10661.
80. Russo J & Russo IH 1999 Cellular basis of breast cancer susceptibility. Oncology Research 11 169-178.
81. Russo J, Ao X, Grill C & Russo IH 1999 Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Research and Treatment 53 217-227.
82. Schena M, Shalon D, Davis RW & Brown PO 1995 Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 467-470.
83. Schwab M & Amler LC 1990 Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer. Genes, Chromosomes and Cancer 1 181-193.
84. Scully R & Livingston DM 2000 In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408 429-432.
85. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC & Wu CW 2000 Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Research 60 3884-3892.
86. Sherlock G 2000 Analysis of large-scale gene expression data. Current Opinion in Immunology 12 201-205.
87. Simon R, Radmacher MD & Dobbin K 2002 Design of studies using DNA microarrays. Genetic Epidemiology 23 21-36.
88. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A & McGuire WL 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 177-182.
89. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J & Norton L 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 344 783-792.
90. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP & Borresen-Dale AL 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874.
91. Sotiriou C, Khanna C, Jazaeri AA, Petersen D & Liu ET 2002a Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. Journal of Molecular Diagnostics 4 30-36.
92. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK & Liu ET 2002b Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Research 4 1-8.
93. Sparano JA 2001 Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Seminars in Oncology 28 20-27.
94. Tan AR & Swain SM 2001 Adjuvant chemotherapy for breast cancer: an update. Seminars in Oncology 28 359-376.
95. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H & Eyfjord JE 1998 Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352 1337-1339.
96. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP & Sauter G 2001 Tissue microarrays for rapid linking of molecular changes to clinical endpoints. American Journal of Pathology 159 2249-2256.
97. Tremblay PJ, Pothier F, Hoang T, Tremblay G, Brownstein S, Liszauer A & Jolicoeur P 1989 Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues. Molecular and Cellular Biology 9 854-859.
98. Tzeng YJ, Guhl E, Graessmann M & Graessmann A 1993 Breast cancer formation in transgenic animals induced by the whey acidic protein SV40 T antigen (WAP-SV-T) hybrid gene. Oncogene 8 1965-1971.
99. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD & Eberwine JH 1990 Amplified RNA synthesized from limited quantities of heterogeneous cDNA. PNAS 87 1663-1667.
100. Van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der KK, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R & Friend SH 2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 530-536.
101. Wang E, Miller LD, Ohnmacht GA, Liu ET & Marincola FM 2000 High-fidelity mRNA amplification for gene profiling. Nature Biotechnology 18 457-459.
102. Wang Y, Lu J, Lee R, Gu Z & Clarke R 2002 Iterative normalization of cDNA microarray data. IEEE Trans Information Technology in Biomedicine 6 29-37.
103. Webster MA & Muller WJ 1994 Mammary tumorigenesis and metastasis in transgenic mice. Seminars in Cancer Biology 5 69-76.
104. Wolff AC & Davidson NE 2001 Use of SERMs for the adjuvant therapy of early-stage breast cancer. Annals of the New York Academy of Sciences 949 80-88.
105. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C & Micklem G 1995 Identification of the breast cancer susceptibility gene BRCA2. Nature 378 789-792.
106. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M & Hiraga T 1999 Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treatment Reviews 25 293-299.
107. Yoshidome K, Shibata MA, Couldrey C, Korach KS & Green JE 2000 Estrogen promotes mammary tumor development in C3(1)/SV40 large T- antigen transgenic mice: paradoxical loss of estrogen receptor alpha expression during tumor progression. Cancer Research 60 6901-6910.